Gapping down
In reaction to disappointing earnings/guidance: CPLP -38.6%, ACPW -22.5%,CNI -7%, WHR -5.3%, NBR -5%, CNX -4.2%, STLY -3.9%, WDR -3.4%, ABX-2.4%, CDNS -2.1%, (also CFO Geoff Ribar to retire effective March 31), HSY-2.1%, LLY -1.6%, ESRX -1.2%, (also announced Paz will retire as CEO on May 4 and stay on as Chairman of the Company; Tim Wentworth will assume the role of CEO on May 4), AGNC -1.1%, FBC -1.1%, AHGP -0.9%, B -0.8%, LMT-0.8%, GLW -0.7%, WAT -0.5%
Other news: CPRX -54% (provides regulatory update on Firdapse, FDA states additional 'positive' results from a well-controlled study in patients with LEMS will need to be submitted, notes cash balance of ~$52 mln as of Mar 31),SRPT -45.1% (issues statement on Advisory Committee; committee voted 6-7 against the finding of substantial evidence showing eteplirsen induces production of dystrophin to a level that is reasonably likely to predict clinical benefit), DRRX -9.9% (commences common stock offering), -9.8% (acquires exclusive US rights to Zurampic from AstraZeneca (AZN)), MCUR -9% (following 40%+ move higher on Monday), PRGO -1.9% (cont weakness), AZN-1.4% (likely in sympathy with LLY earnings), GSK -0.9% (likely in sympathy with LLY earnings), AAPL -0.7% (still checking, trading lower pre-mkt with earnings to be released AMC)
Analyst comments: DDD -2.6% (downgraded to Hold from Buy at Needham)
In reaction to disappointing earnings/guidance: CPLP -38.6%, ACPW -22.5%,CNI -7%, WHR -5.3%, NBR -5%, CNX -4.2%, STLY -3.9%, WDR -3.4%, ABX-2.4%, CDNS -2.1%, (also CFO Geoff Ribar to retire effective March 31), HSY-2.1%, LLY -1.6%, ESRX -1.2%, (also announced Paz will retire as CEO on May 4 and stay on as Chairman of the Company; Tim Wentworth will assume the role of CEO on May 4), AGNC -1.1%, FBC -1.1%, AHGP -0.9%, B -0.8%, LMT-0.8%, GLW -0.7%, WAT -0.5%
Other news: CPRX -54% (provides regulatory update on Firdapse, FDA states additional 'positive' results from a well-controlled study in patients with LEMS will need to be submitted, notes cash balance of ~$52 mln as of Mar 31),SRPT -45.1% (issues statement on Advisory Committee; committee voted 6-7 against the finding of substantial evidence showing eteplirsen induces production of dystrophin to a level that is reasonably likely to predict clinical benefit), DRRX -9.9% (commences common stock offering), -9.8% (acquires exclusive US rights to Zurampic from AstraZeneca (AZN)), MCUR -9% (following 40%+ move higher on Monday), PRGO -1.9% (cont weakness), AZN-1.4% (likely in sympathy with LLY earnings), GSK -0.9% (likely in sympathy with LLY earnings), AAPL -0.7% (still checking, trading lower pre-mkt with earnings to be released AMC)
Analyst comments: DDD -2.6% (downgraded to Hold from Buy at Needham)